

## Special Issue

# Safety and Effectiveness of COVID-19 Vaccines on COVID-19 Infection and Its Long-Term Consequences

### Message from the Guest Editor

The COVID-19 pandemic resulted in several health and financial problems, and the relevant vaccines urgently developed during this crisis were able to reduce the number of deaths and disease burdens. The persistence of COVID-19 infection after vaccination encourages the possibility of new vaccines to be used as booster strategies for new SARS-COV-2 variants. Additionally, it is important to unveil if current vaccines are able to avoid the long-term consequences of COVID-19 infection. Thus, this Special Issue will focus on the safety and effectiveness of COVID-19 vaccines in COVID-19 infection and their long-term consequences. Topics that can be explored include: new vaccines against COVID-19, the safety and efficacy of vaccines in clinical trials, and an analysis of the effects of vaccination on the COVID-19 recovery and the long-term infection consequences. We believe that sharing new knowledge on these subjects may lead to the better development of new vaccines or improve the current vaccines against COVID-19 to avoid the infection's long-term consequences.

### Guest Editor

Dr. Ana Paula Junqueira-Kipnis

Department of Biosciences and Technology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia 74605-050, Brazil

### Deadline for manuscript submissions

closed (31 December 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/133677](https://mdpi.com/si/133677)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).